Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting

Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysf...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of hematology and oncology Vol. 18; no. 1; pp. 28 - 4
Main Authors:	Bu, Qiling, Zhu, Hong-Hu, Chen, Wenming
Format:	Journal Article
Language:	English
Published:	London BioMed Central 07.03.2025 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Amyloid Amyloidosis Antigens Cancer Research Clinical trials Conferences, meetings and seminars Correspondence Drug dosages Hematology Humans Immunoglobulin light chain amyloidosis Immunoglobulin Light Chains - metabolism Immunoglobulin Light-chain Amyloidosis - drug therapy Immunoglobulin Light-chain Amyloidosis - therapy Immunoglobulins Latest updates from major conferences Light Light chains Medicine Medicine & Public Health Molecular Targeted Therapy - methods Monoclonal antibodies Multiple myeloma Oncology Peptides Plasma cells Remission Response rates Targeted therapies Targeted therapies Clinical trials Immunoglobulin light chain amyloidosis
ISSN:	1756-8722, 1756-8722
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!